Institute of Pathology and Neuropathology, Eberhard Karls University of Tübingen and Comprehensive Cancer Center, Tübingen University Hospital, Tübingen, Germany.
Lymphoid Malignancies Unit, Hospital Henri Mondor, APHP, Inserm U955, University of Paris-East, Creteil, France.
Mod Pathol. 2019 Jul;32(8):1123-1134. doi: 10.1038/s41379-019-0254-4. Epub 2019 Apr 5.
Angioimmunoblastic T-cell lymphoma is a peripheral T-cell lymphoma derived from follicular T-helper cells. High-throughput genomic sequencing studies have shown that angioimmunoblastic T-cell lymphoma carries frequent mutations in RHOA and IDH2 genes. The clinico-pathological features of angioimmunoblastic T-cell lymphoma cases with RHOA mutations have been addressed; however, similar studies for IDH2 mutated cases are lacking. Therefore, the aim of the present study was to evaluate the pathological features of angioimmunoblastic T-cell lymphoma with IDH2 mutations. In order to identify cases with IDH2 mutations, 50 cases previously diagnosed as angioimmunoblastic T-cell lymphoma were subjected to next-generation sequencing analysis using a custom panel covering four genes frequently mutated in angioimmunoblastic T-cell lymphoma including DNMT3A, TET2, IDH2 and RHOA. All cases were analyzed for PD1, ICOS, CXCL13, CD10, BCL6, CD21, CD23 and EBER in situ hybridization. Mutational analysis recognized three groups. Group 1: IDH2 mutations were identified in 20 cases (40%). All cases carried RHOA mutations. Group 2: RHOA mutations without IDH2 mutation were identified in 16 cases (32%), and Group 3: 14 cases (28%) without RHOA or IDH2 mutations. Morphologically, angioimmunoblastic T-cell lymphoma cases with IDH2 mutations were characterized by the presence of medium to large clear cells (p = 0.00001), and a follicular T-helper phenotype with the particular feature of strong CD10 (p = 0.0268) and CXCL13 expression (p = 0.0346). Interestingly, TET2 mutations were identified in 32 of 33 (97%) cases with IDH2 and/or RHOA mutations whereas only 55% of angioimmunoblastic T-cell lymphoma cases wild-type for these two genes carried TET2 mutations (p = 0.0022). In contrast, DNMT3A mutations were found in 48% of the cases and were equally distributed in the three groups. In conclusion, our results support the results of gene expression profiling studies suggesting that IDH2 mutations define a unique subgroup within angioimmunoblastic T-cell lymphoma with strong follicular T-helper-like phenotype and characteristic morphological features.
血管免疫母细胞性 T 细胞淋巴瘤是一种来源于滤泡辅助 T 细胞的外周 T 细胞淋巴瘤。高通量基因组测序研究表明,血管免疫母细胞性 T 细胞淋巴瘤中经常发生 RHOA 和 IDH2 基因的突变。已经研究了 RHOA 突变的血管免疫母细胞性 T 细胞淋巴瘤病例的临床病理特征;然而,缺乏 IDH2 突变病例的类似研究。因此,本研究旨在评估 IDH2 突变的血管免疫母细胞性 T 细胞淋巴瘤的病理特征。为了鉴定 IDH2 突变病例,对 50 例先前诊断为血管免疫母细胞性 T 细胞淋巴瘤的病例进行了下一代测序分析,使用了一个包含四个在血管免疫母细胞性 T 细胞淋巴瘤中经常发生突变的基因的定制面板,包括 DNMT3A、TET2、IDH2 和 RHOA。所有病例均进行 PD1、ICOS、CXCL13、CD10、BCL6、CD21、CD23 和 EBER 原位杂交分析。突变分析识别出三个组。第 1 组:在 20 例(40%)病例中发现 IDH2 突变。所有病例均携带 RHOA 突变。第 2 组:在 16 例(32%)病例中发现 RHOA 突变而无 IDH2 突变,第 3 组:在 14 例(28%)病例中无 RHOA 或 IDH2 突变。形态学上,具有 IDH2 突变的血管免疫母细胞性 T 细胞淋巴瘤病例的特征是存在中等至大的透明细胞(p=0.00001),以及具有滤泡辅助 T 细胞表型的特征,表现为强烈的 CD10(p=0.0268)和 CXCL13 表达(p=0.0346)。有趣的是,在 33 例具有 IDH2 和/或 RHOA 突变的病例中,发现了 32 例(97%)TET2 突变,而在这两个基因野生型的血管免疫母细胞性 T 细胞淋巴瘤病例中,仅有 55%携带 TET2 突变(p=0.0022)。相反,DNMT3A 突变发生在 48%的病例中,在三组中分布均匀。总之,我们的结果支持基因表达谱研究的结果,表明 IDH2 突变定义了血管免疫母细胞性 T 细胞淋巴瘤中的一个独特亚群,具有强烈的滤泡辅助 T 细胞样表型和特征性的形态学特征。